Medical Marijuana, Inc. (MJNA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Medical Marijuana, Inc. (MJNA) trades at $0.0001 with AI Score 47/100 (Grade C). Medical Marijuana, Inc. operates in the cannabinoid-based nutraceutical sector, focusing on the development, sale, and distribution of hemp oil containing naturally occurring cannabinoids. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for MJNA: MJNA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MJNA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MJNA: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Medical Marijuana, Inc. (MJNA) Healthcare & Pipeline Overview
Medical Marijuana, Inc. is an investment holding company in the cannabinoid-based nutraceutical industry, developing and distributing hemp oil and CBD products. Its diversified portfolio includes nutraceuticals, skincare, and pet products, targeting health and wellness markets. The company operates in a competitive landscape with evolving regulatory environments.
What Is the Investment Thesis for MJNA?
Medical Marijuana, Inc. presents a speculative investment opportunity within the rapidly expanding cannabinoid market. The company's diverse product portfolio, including CBD-rich hemp oil, dietary supplements, and pet products, allows it to capture various segments of the health and wellness market. With a P/E ratio of 19.73 and a profit margin of 0.7%, the company shows potential for profitability, although the market capitalization remains at $0.00B as of 2026-03-16. Growth catalysts include expanding distribution channels and continued product innovation. However, investors should be aware of potential risks such as regulatory uncertainty surrounding CBD products and intense competition from other players in the cannabinoid market. The company's ability to navigate these challenges will be crucial for its long-term success.
Based on FMP financials and quantitative analysis
MJNA Key Highlights
Market Cap of $0.00B reflects its current valuation in the market.
- P/E Ratio of 19.73 indicates the price investors are willing to pay for each dollar of earnings.
- Profit Margin of 0.7% shows the percentage of revenue that turns into profit.
- Gross Margin of 76.7% suggests efficient production and pricing strategies.
- Beta of 0.61 indicates lower volatility compared to the overall market.
Who Are MJNA's Competitors?
MJNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MJNA's Key Strengths?
Diverse product portfolio.
- Proprietary testing and standardization methods.
- Established brands like Kannaway and HempMeds.
- Focus on both human and animal health and wellness.
What Are MJNA's Weaknesses?
Limited market capitalization.
- Low profit margin.
- Dependence on regulatory approvals.
- Intense competition in the cannabinoid market.
What Could Drive MJNA Stock Higher?
MJNA catalyst: Potential regulatory changes in key markets could positively impact the company's ability to sell and distribute its products.
- Continued expansion of the CBD market is driving increased demand for the company's products.
- Research and development efforts could lead to the discovery of new therapeutic applications for cannabinoids.
- Strategic partnerships and acquisitions could provide access to new markets and technologies.
What Are the Key Risks for MJNA?
Financial-distress signal — its Altman Z-Score of -3.26 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-1.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory uncertainty surrounding CBD products could negatively impact the company's operations.
- Intense competition from other players in the cannabinoid market could erode market share.
- Negative publicity related to cannabis products could damage the company's reputation.
- Fluctuations in raw material prices could impact profitability.
- The company's reliance on the OTC market exposes it to higher levels of risk and scrutiny.
What Are the Growth Opportunities for MJNA?
- Expansion into New Therapeutic Areas: Medical Marijuana, Inc. has the opportunity to expand its research and development efforts to explore new therapeutic applications for cannabinoids. The global market for cannabis-based pharmaceuticals is projected to reach $4.9 billion by 2028. Focusing on developing targeted therapies for specific conditions could drive significant revenue growth and establish the company as a leader in cannabinoid-based medicine. This expansion requires significant investment in R&D and clinical trials, with potential product launches in the next 3-5 years.
- Geographic Market Expansion: The company can pursue geographic expansion into new markets, particularly in Europe and Asia, where the demand for CBD products is growing rapidly. Entering these markets requires navigating complex regulatory landscapes and establishing strategic partnerships with local distributors. Successful expansion could significantly increase the company's revenue base and global presence within the next 2-3 years.
- Product Innovation and Diversification: Medical Marijuana, Inc. can drive growth through continuous product innovation and diversification. Developing new CBD-infused products, such as beverages, edibles, and topical creams, can attract a wider range of consumers. The global CBD consumer health market is projected to reach $43 billion by 2033. Investing in product development and marketing can help the company capture a larger share of this growing market within the next 1-2 years.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with established companies in the health and wellness sector can provide Medical Marijuana, Inc. with access to new distribution channels and technologies. Acquiring smaller companies with complementary product lines or technologies can also accelerate growth. The mergers and acquisitions activity in the cannabis industry is expected to remain strong, with deals valued at over $5 billion annually. These partnerships and acquisitions can enhance the company's competitive position and market reach within the next 1-3 years.
- Development of Proprietary Testing and Standardization Methods: Medical Marijuana, Inc. can leverage its proprietary testing, genetics, labeling and packaging, tracking, and production and standardization methods to differentiate itself from competitors. The demand for high-quality, standardized CBD products is increasing as consumers become more aware of the potential risks associated with unregulated products. By establishing itself as a leader in quality control and standardization, the company can build trust with consumers and gain a competitive advantage. These methods can be further refined and marketed to other companies in the industry within the next year.
What Are MJNA's Competitive Advantages?
- Proprietary testing and standardization methods.
- Established brands like Kannaway and HempMeds.
- Diverse product portfolio targeting multiple market segments.
What Does MJNA Do?
Incorporated in 2005 and based in San Diego, California, Medical Marijuana, Inc. operates as an investment holding company within the burgeoning cannabinoid-based nutraceutical industry. The company's primary focus revolves around the development, sale, and distribution of hemp oil containing naturally occurring cannabinoids, most notably cannabidiol (CBD). Its product range extends beyond basic hemp oil to include various CBD-rich products, catering to a growing consumer demand for natural health and wellness solutions. Medical Marijuana, Inc. is also involved in researching and developing new therapeutic agents designed to reduce oxidative stress and act as immuno-modulators and neuroprotectants. The company markets dietary supplements, skin care products, and prescription-based hemp oil under the Kannaway and HempMeds brands. It also provides proprietary testing, genetics, labeling and packaging, tracking, and production and standardization methods for the medicinal cannabinoid industry. Furthermore, Medical Marijuana, Inc. offers RSHO oil for treating various illnesses and conditions, and plant-based, non-GMO pet products for health and wellness, play and wear, and environmentally-friendly supplies, demonstrating a commitment to both human and animal well-being.
What Products and Services Does MJNA Offer?
- Develops and sells hemp oil containing naturally occurring cannabinoids, including CBD.
- Offers a range of CBD-rich products targeting health and wellness.
- Conducts research and development of new therapeutic agents.
- Markets dietary supplements, skin care products, and prescription-based hemp oil under the Kannaway and HempMeds brands.
- Provides proprietary testing, genetics, labeling and packaging, tracking, and production and standardization methods for the medicinal cannabinoid industry.
- Offers RSHO oil for the treatment of various illnesses and conditions.
- Provides plant-based, non-GMO pet products for health and wellness.
How Does MJNA Make Money?
- Develops and manufactures cannabinoid-based products.
- Sells products through online channels and distributors.
- Generates revenue from product sales and licensing of proprietary technologies.
What Industry Does MJNA Operate In?
Medical Marijuana, Inc. operates within the rapidly evolving cannabinoid-based nutraceutical industry. This sector has experienced significant growth due to increasing consumer interest in natural health and wellness solutions. The market is characterized by intense competition, with numerous companies vying for market share. Regulatory uncertainty remains a key challenge, as laws governing CBD and hemp products vary widely across different jurisdictions. Medical Marijuana, Inc. aims to differentiate itself through its diverse product portfolio and proprietary testing and standardization methods.
Who Are MJNA's Key Customers?
- Individuals seeking natural health and wellness solutions.
- Patients looking for alternative treatments for various illnesses and conditions.
- Pet owners seeking plant-based, non-GMO products for their pets.
Company Profile
Medical Marijuana, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vista, US. The company is led by CEO Timothy Richard Scott. MJNA has traded publicly since 2010.
Medical Marijuana, Inc. Financial Trajectory
Medical Marijuana, Inc. (MJNA) reported $2.5M in revenue for Q1 2026, a decline of 37.9% compared to the prior quarter. The company recorded net income of $167K, with diluted EPS of $0.00. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, MJNA averaged $0.00 in diluted EPS.
How Medical Marijuana, Inc. Is Valued
Relative to its peer group, MJNA's quantitative score of 47/100 is below the peer average of 62/100.
Key Financial Metrics
Return on equity for Medical Marijuana, Inc. stands at -1.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.4%, showing how much profit it generates from its asset base. A current ratio of 0.74 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -45.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Medical Marijuana, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.26 places it in the distress zone, a signal of elevated financial risk.
MJNA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in upcoming growth.
- Social sentiment has shifted positively, with increased discussions around the potential for cannabis legalization and its impact on MJNA.
- The company has been actively expanding its product lines, tapping into new markets which could enhance revenue streams.
- Positive media coverage regarding the cannabis industry has boosted investor interest, translating into a more favorable perception of MJNA.
Bear Case
- Concerns remain about regulatory hurdles that could hinder growth, creating uncertainty around the company's long-term viability.
- Social sentiment is mixed, with some community discussions highlighting skepticism about MJNA's ability to compete with larger players in the market.
- Recent earnings reports have shown inconsistent performance, leading to doubts about the company's financial health and operational efficiency.
- Market sentiment has been impacted by broader economic concerns, which may affect investor appetite for stocks in the cannabis sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2M | $166,931 | $0.00 |
| Q4 2025 | $4M | -$1M | $0.00 |
| Q3 2025 | $3M | $12,744 | $0.00 |
| Q2 2025 | $3M | -$128,187 | $0.00 |
Based on FMP financials and quantitative analysis
MJNA Latest News
No recent news available for MJNA.
MJNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MJNA.
Price Targets
Wall Street price target analysis for MJNA.
MJNA MoonshotScore
What does this score mean?
The MoonshotScore rates MJNA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Timothy Richard Scott
CEO
Timothy Richard Scott serves as the CEO of Medical Marijuana, Inc., overseeing the company's operations and strategic direction. His background includes experience in managing and growing companies within the health and wellness sector. He is responsible for guiding the company's efforts in the cannabinoid-based nutraceutical industry, focusing on the development, sale, and distribution of hemp oil and CBD products. His leadership is crucial in navigating the complex regulatory landscape and driving the company's growth initiatives.
Track Record: Under Timothy Richard Scott's leadership, Medical Marijuana, Inc. has focused on expanding its product portfolio and market reach. Key achievements include the development of new CBD-infused products and the establishment of strategic partnerships. His strategic decisions have aimed to position the company as a leader in the cannabinoid-based nutraceutical industry. He manages 91 employees.
MJNA OTC Market Information
The OTC Other tier, where Medical Marijuana, Inc. trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This tier is generally considered the most speculative and carries the highest risk compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies on the OTC Other tier are not required to adhere to the same stringent reporting standards as those on higher tiers or major exchanges, leading to less transparency for investors.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in Medical Marijuana, Inc.
- Low liquidity can make it difficult to buy or sell shares.
- Wide bid-ask spreads can increase transaction costs.
- Potential for fraud or manipulation is higher on the OTC Other market.
- Regulatory uncertainty surrounding CBD products adds to the risk.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Understand the regulatory environment and potential risks.
- Evaluate the company's liquidity and trading volume.
- Consult with a financial advisor before investing.
- The company has been in operation since 2005.
- Medical Marijuana, Inc. has a diverse product portfolio.
- The company has established brands like Kannaway and HempMeds.
MJNA Healthcare Stock FAQ
What does the AI Score mean for MJNA?
MJNA holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Medical Marijuana, Inc. operates in the cannabinoid-based nutraceutical sector, focusing on the development, sale, and distribution of hemp oil containing naturally occurring cannabinoids. …
What does Medical Marijuana, Inc. do?
Medical Marijuana, Inc. operates as an investment holding company within the cannabinoid-based nutraceutical industry. Its core business involves the development, sale, and distribution of hemp oil containing naturally occurring cannabinoids, including cannabidiol (CBD). The company offers a diverse range of CBD-rich products, including dietary supplements, skin care products, and pet products, targeting the growing health and wellness market.
What do analysts say about MJNA stock?
As of 2026-03-16, formal analyst coverage of Medical Marijuana, Inc. (MJNA) is limited due to its OTC listing and smaller market capitalization. Key valuation metrics include a P/E ratio of 19.73 and a profit margin of 0.7%. Growth considerations center on the company's ability to expand its product portfolio, enter new markets, and navigate the evolving regulatory landscape.
What are the main risks for MJNA?
Medical Marijuana, Inc. faces several key risks, including regulatory uncertainty surrounding CBD products, intense competition from other players in the cannabinoid market, and potential negative publicity related to cannabis products. The company's reliance on the OTC market exposes it to higher levels of risk and scrutiny.
What are the key growth opportunities for MJNA in healthcare?
Medical Marijuana, Inc.'s growth opportunities in healthcare lie in expanding into new therapeutic areas, such as developing targeted therapies for specific conditions like pain management, anxiety, and sleep disorders. The company can also focus on developing prescription-based hemp oil products and conducting clinical trials to validate the efficacy of its products.
How does Medical Marijuana, Inc. navigate regulatory approval processes?
Medical Marijuana, Inc. navigates regulatory approval processes by adhering to current regulations and proactively engaging with regulatory bodies. The company focuses on ensuring that its products meet quality and safety standards and complies with labeling requirements. As the regulatory landscape for CBD and hemp products evolves, Medical Marijuana, Inc. monitors changes and adapts its strategies accordingly.
What are the key factors to evaluate for MJNA?
Medical Marijuana, Inc. (MJNA) holds an AI score of 47/100 (low). presents a speculative investment opportunity within the rapidly expanding cannabinoid market. Not financial advice.
How frequently does MJNA data refresh on this page?
MJNA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MJNA's recent stock price performance?
Medical Marijuana, Inc. (MJNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Financial data may be limited or unaudited.